Reported about 7 hours ago
The U.S. government has announced that Wegovy, Novo Nordisk's weight-loss drug, is among the 15 medicines set for Medicare price negotiations in 2027. This inclusion may lead to price cuts, potentially increasing access to GLP-1 drugs for those over 65, although it does not resolve issues for uninsured patients. The impact on sales is expected to be limited, as many prescriptions already go through discounted channels. The negotiated prices will not consider existing rebates and cuts, indicating that the overall effect might be modest.
Source: YAHOO